NCT00875771

Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients

Phase II Study of Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine efficacy and safety of the biweekly scheme with Capecitabine and Irinotecan, plus bevacizumab in patients with metastatic colorectal cancer.

Detailed description

The purpose of this study is to determine efficacy and safety of the biweekly scheme with Capecitabine and Irinotecan, plus bevacizumab in patients with metastatic colorectal cancer. * Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks * Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks * Bevacizumab: 5 mg/kg day 1, every 2 Weeks

Conditions

• Metastatic Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Capecitabine+Irinotecan+Bevacizumab	* Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks * Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks * Bevacizumab: 5 mg/kg day 1, every 2 Weeks Treatment will be given until disease progression or unacceptable toxicity.

Timeline

• Start date: 2009-04-01
• Primary completion: 2012-05-01
• Completion: 2012-05-01
• First posted: 2009-04-03
• Last updated: 2017-08-01

Locations

1 site across 1 country: Spain